ACC.24: Late-Breaking Science Video Collection
Published: 06 April 2024
-
Views:
5943
-
Likes:
7
-
Views:
5943
-
Likes:
7
-
Up Next -
3m 37s -
4m 35sPart 3 | Session 9 Technology-Assisted Nonprescription Rosuvastatin: TACTiC -
4m 45sPart 3 | Session 10 Coronary Sinus Reducer in Refractory Angina: ORBITA COSMIC -
2m 30sPart 3 | Session 11 TAVI Vs SAVR in Patients with Severe Aortic Valve Stenosis: DEDICATE-DZHK6 -
4m 17s
-
6m 45sPart 4 | Session 1 Artificial Intelligence in Cardiology: What You Need to Know in 2024 -
6m 21sPart 4 | Session 2 Weight Loss Medications: What You Need to Know in 2024
-
43m 48sPart 1 | Session 1 ACC.24 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
28m 9sPart 1 | Session 2 What's Hot at ACC.24? Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen
-
22m 43sPart 2 | Session 1 Late-Breaker Discussion: The EMPACT-MI Trial Harriette Van Spall, Javed Butler
-
14m 7sPart 2 | Session 2 Late-Breaker Discussion: The AEGIS-II Trial Michael C Gibson, Harriette Van Spall
-
29m 8sPart 2 | Session 3 Late-Breaker Discussion: The RELIEVE-HF Trial Gregg Stone, Harriette Van Spall
-
23m 6sPart 2 | Session 4 Late-Breaker Discussion: The ARISE-HF Trial Harriette Van Spall, James L Januzzi
-
5m 50sPart 3 | Session 1 Gamification and Financial Incentives to Increase PA Among Patients at Elevated Cardiovascular Risk Alexander Fanaroff
-
7m 49sPart 3 | Session 2 Zilbesiran in Patients With Hypertension: KARDIA-2 Akshay S Desai
-
3m 40sPart 3 | Session 3 Olezarsen in Adults with Hypertriglyceridemia and ASCVD and/or Severe Hypertriglyceridemia Brian Bergmark
-
7m 18sPart 3 | Session 4 Lerodalcibep in Patients With High Risk For Cardiovascular Disease on Stable Lipid-Lowering Therapy Evan A Stein
-
6m 40sPart 3 | Session 5 Chelation Therapy in Post-MI Pts with Diabetes: TACT2 Gervasio L Lamas
-
6m 41sPart 3 | Session 6 Semaglutide in Patients with HfpEF, Obesity and Diabetes: STEP HFpEF Mikhail Kosiborod
Overview
Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.
To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.
For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
More from this programme
Part 1
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24.
Part 2
Late-Breaker Discussion Series
Host, Dr Harriette Van Spall is joined by principal investigators for discussion on selected late-breaking trials.
Part 3
Expert Interviews
Expert Interviews conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.
Part 4
Highlights
Part 5
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
About the episode
ACC.24 — Investigator, Dr Howard C Hermann (Penn Medicine, Philadelphia, PA, US) joins us to discuss the findings from the SMART Trial (NCT04722250).
This prospective, multi-center, randomized controlled study aims to investigate the valve safety and performance of self expanding as compared to balloon-expandable transcatheter aortic valve replacement (TAVR) in patients with small aortic annuli and severe symptomatic aortic stenosis. At select sites, a stress echocardiography sub-study also evaluated the performance of self expandable and balloon-expandable TAVR in this patient group, after exercise stress testing.
716 patients were enrolled in the trial, and were randomized on a 1:1 basis to receive TAVR with either a Medtronic self-expanding transcatheter aortic valve, or an Edwards balloon-expandable transcatheter heart valve.
Findings showed that the trial met both primary endpoints, with no significant difference between groups in terms of a composite of death, disabling stroke or rehospitalization for heart failure, which occurred in 9.5% of patients with the self-expandable valve, and 10.6 of those with the balloon-expandable valve. In terms of valve function, the self-expandable valve was found to be superior in a composite of structural and non-structural valve deterioration, blood clotting around the valve, infection of the valve and aortic valve reintervention.
Interview Questions:
- What is the importance of this study?
- Could you tell us a bit more about the devices used in this study, and why SE and BE devices are compared in this patient group?
- What are the key findings?
- What is the impact of these findings on clinical practice?
- What is your take-home message?
- What further research is required?
Recorded onsite at the ACC Conference in Atlanta, 2024.
Faculty Biographies
Howard C Herrmann
Director, Cardiac Catheterization Laboratories
Howard C Herrmann, MD, is a Professor of Medicine at the University of Pennsylvania School of Medicine and Director of Interventional Cardiology and the Cardiac Catheterization Laboratories at the Hospital of the University of Pennsylvania, Philadelphia. He has authored or co-authored more than 200 articles on numerous topics in interventional cardiology. His research focuses on the clinical investigation of new therapies for valvular and structural heart disease. He is Past President of the Pennsylvania Chapter of the American College of Cardiology (ACC) and serves on numerous national committees and Editorial Boards. Dr Herrmann earned his AB at Harvard College and his MD at Harvard Medical School, and completed his training at Massachusetts General Hospital.
Comments